

## Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

John F. Seymour,<sup>1</sup> Robert Marcus,<sup>2</sup> Andrew Davies,<sup>3</sup> Eve Gallop-Evans,<sup>4</sup> Andrew Grigg,<sup>5</sup> Andrew Haynes,<sup>6</sup> Michael Herold,<sup>7</sup> Thomas Illmer,<sup>8</sup> Herman Nilsson-Ehle,<sup>9</sup> Martin Sökler,<sup>10</sup> Ulrich Dünzinger,<sup>11</sup> Tina Nielsen,<sup>12</sup> Aino Launonen<sup>12</sup> and Wolfgang Hiddemann<sup>13</sup>

<sup>1</sup>Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Victoria, NSW, Australia; <sup>2</sup>Kings College Hospital, London, UK; <sup>3</sup>Cancer Research UK Centre, University of Southampton, Southampton, UK; <sup>4</sup>Velindre Cancer Centre, Cardiff, UK; <sup>5</sup>Austin Hospital, Melbourne, Victoria, NSW, Australia; <sup>6</sup>Nottingham University Hospitals NHS Trust, Nottingham, UK; <sup>7</sup>HELIOS-Klinikum Erfurt, Germany; <sup>8</sup>BAG Freiberg-Richter, Jacobasch, Illmer and Wolf, Dresden, Germany; <sup>9</sup>Section of Hematology and Coagulation, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>10</sup>Eberhard-Karls-University Tübingen, Tübingen, Germany; <sup>11</sup>Roche Pharma AG, Grenzach-Wyhlen, Germany; <sup>12</sup>F. Hoffmann-La Roche Ltd., Basel, Switzerland and <sup>13</sup>Department of Medicine III, Ludwig-Maximilians-University, München, Germany

doi:10.3324/haematol.2020.246991

©2020 Ferrata Storti Foundation

In the article by Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, Herold M, Illmer T, Nilsson-Ehle H, Sökler M, Dünzinger U, Nielsen T, Launonen A, Hiddemann W entitled 'Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression', published in *Haematologica* supplement 2019 Jun;104(6):1202-1208, there is a small data error in the *Online Supplementary Table S6*, the number of low-risk FLIPI patients with POD24 in the G-chemo group percentage has been miscalculated, it should read (9.4) not (44.4).

Online Supplementary Table S6. POD24 and post-progression mortality rates, stratified by FLIPI score category.

FLIPI score category	Number of POD24 patients (n/N, %)		24-month CIF rate, % (95% CI)		POD24 risk reduction, % (95% CI)	2-year PPS		Crude PPS death rates	
	G-chemo	R-chemo	G-chemo	R-chemo		G-chemo	R-chemo	G-chemo	R-chemo
<b>High</b>	30/249 (12.0)	54/253 (21.3)	12.7 (8.8-17.3)	22.2 (17.2-27.6)	46.4 (16.2-65.7)	0.60	0.56	26.07 (15.3-44)	27.65 (18.8-40.6)
<b>Intermediate</b>	15/225 (6.7)	31/223 (13.9)	7.2 (4.2-11.2)	14.8 (10.4-20.0)	54.6 (15.8-75.5)	0.86	0.73	6.62 (1.7-26.5)	13.99 (7-28)
<b>Low</b>	12/127 (9.4)	13/125 (10.4)	10.0 (5.5-16.2)	11.6 (6.5-18.3)	15.0 (-83.3-61.2)	0.73	0.77	11.86 (3.8-36.8)	10.67 (3.4-33.1)

CI: confidence interval; FLIPI: Follicular Lymphoma International Prognostic Index; G-chemo: obinutuzumab plus chemotherapy; POD: progressive disease or death; PPS: post-progression survival; R-chemo: rituximab plus chemotherapy.